Listed as “Ventus Therapeutics”
- First observed:
- 1 Nov 2026
- Investment announced:
- Date not recorded
Ventus Therapeutics develops therapeutics directed at innate immune pathways.
Ventus Therapeutics uses structural immunology to discover and develop therapeutics. Its research focuses on innate immune pathways as targets for addressing human health conditions through therapeutics.
Bio + Health
Category source ↗Checked
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Ventus Therapeutics”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.